The Parkinson's Progression Markers Initiative (PPMI)
The purpose of this research study is to collect clinical information, samples of blood, urine, spinal fluid, and brain images from 1) people with Parkinson Disease (PD) 2) people who may be at risk to develop PD, and 3) healthy controls
The information collected in this study will be used to help develop biomarkers for PD. Biomarkers are measures that may help us to understand how PD changes over time and may help us test drugs to treat the disease in the future.
1) Parkinson disease (PD) 2) Have a positive genetic mutation in the LRRK2, SNCA or GBA gene 3) Healthy controls
This study is currently recruiting 1) Healthy people of Ashkenazi Jewish, Greek, or Italian heritage with a family history of PD 2) People who know from prior genetic testing (in a clinic or through “23andMe”, for example) that they carry a "risk" gene for PD called LRRK2, SNCA or GBA. 3) Healthy people with a first degree relative (parent, sibling or child) who is known to carry a mutation in the LRRK2, GBA or SNCA genes. 4) People with Parkinson's disease and of Ashkenazi Jewish, Greek, or Italian heritage.
The study has completed recruitment of healthy controls without the family history and ethnicity described above.
Healthy Volunteers Needed
Duration of Participation
For subjects found to carry a LRRK2, GBA or SNCA mutation who choose to participate in the full study, duration of participation will be up to 5 years.
The Michael J. Fox Foundation for Parkinson's Research
There is no reimbursement (or cost to the participant) for the genetic testing pre-screening portion of the study. Subjects subsequently participating in the full study will be paid $50 for completing each of the following visits: the Screening visit, the 3 month, 9 month, 18 month, 30 month and 54 month visit. Subject will be paid $200 for completing each of the following visits: the Baseline visit, the 6 month, 12 month, 24 month, 36 month, 48 month and 60 month visit. If the subject chooses to leave the study early, s/he will only be compensated for the visits completed.